{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T19:51:52Z","timestamp":1783021912510,"version":"3.54.6"},"reference-count":38,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:00:00Z","timestamp":1767830400000},"content-version":"vor","delay-in-days":7,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J of Cosmetic Dermatology"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Recently, the literature has expanded with peer\u2010reviewed studies on immunomodulatory agents' efficacy on scalp psoriasis\u2014which, in turn, widened knowledge gaps regarding these agents' relative effectiveness. We determined the relative efficacy of immunomodulatory monotherapies for scalp psoriasis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We ran Bayesian network meta\u2010analyses (NMAs) using outcomes related to Psoriasis Scalp Severity Index (PSSI) and scalp\u2010specific Physician's Global Assessment of clear (0) or almost clear (1) (Sc\u2010PGA 0\/1).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We estimated the relative efficacy of 22 interventions (including placebo), and analyzed 9 outcomes, namely: proportion of participants who attained Sc\u2010PGA 0\/1, proportion of participants who achieved 100% improvement in PSSI (PSSI\u2010100), and proportion of participants who achieved 90% improvement in PSSI (PSSI\u201090) at 8, 12, and 16\u2009weeks.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>We are the first to provide comparative evidence on the efficacy of newly investigated agents such as deucravacitinib, tildrakizumab, roflumilast and icotrokinra. In general, the IL\u201017 inhibitors (bimekizumab, ixekizumab, secukinumab, brodalumab) and IL\u201023 inhibitors (icotrokinra, guselkumab, tildrakizumab) were effective depending upon the outcome and time\u2010point being considered. At 16\u2009weeks, for PSSI\u2010100, ixekizumab 150\u2009mg at weeks 0, 2, 4, 8, and 12 ranked highest; at 16\u2009weeks, for Sc\u2010PGA 0\/1 bimekizumab 320\u2009mg every 4\u2009weeks ranked highest; at 8\u2009weeks, for PSSI\u2010100 ixekizumab 80\u2009mg every 2\u2009weeks ranked highest; at 8\u2009weeks, for Sc\u2010PGA 0\/1 secukinumab 300\u2009mg at weeks 1, 2, 3 and then every 4\u2009weeks ranked highest. Small\u2010molecule therapies (apremilast, deucravacitinib, roflumilast) improved scalp psoriasis modestly. Our work would guide the design of future studies and clinical decision\u2010making.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/jocd.70662","type":"journal-article","created":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T09:20:21Z","timestamp":1767864021000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Relative Efficacy of Immunomodulatory Monotherapies for Psoriasis of the Scalp: A Network Meta\u2010Analysis Study"],"prefix":"10.1111","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8664-7723","authenticated-orcid":false,"given":"Aditya K.","family":"Gupta","sequence":"first","affiliation":[{"name":"Mediprobe Research Inc.  London Ontario Canada"},{"name":"Division of Dermatology, Temerty Faculty of Medicine University of Toronto  Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary A.","family":"Bamimore","sequence":"additional","affiliation":[{"name":"Mediprobe Research Inc.  London Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tong","family":"Wang","sequence":"additional","affiliation":[{"name":"Mediprobe Research Inc.  London Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Piguet","sequence":"additional","affiliation":[{"name":"Division of Dermatology, Temerty Faculty of Medicine University of Toronto  Toronto Ontario Canada"},{"name":"Division of Dermatology Women's College Hospital  Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0691-640X","authenticated-orcid":false,"given":"Mesbah","family":"Talukder","sequence":"additional","affiliation":[{"name":"School of Pharmacy BRAC University  Dhaka Bangladesh"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,1,8]]},"reference":[{"key":"e_1_2_13_2_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.4006"},{"key":"e_1_2_13_3_1","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.34037"},{"key":"e_1_2_13_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2008.11.890"},{"key":"e_1_2_13_5_1","doi-asserted-by":"publisher","DOI":"10.5826\/dpc.1502a4793"},{"key":"e_1_2_13_6_1","doi-asserted-by":"publisher","DOI":"10.7326\/M14\u20102385"},{"key":"e_1_2_13_7_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13643\u2010024\u201002619\u20109"},{"key":"e_1_2_13_8_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13643\u2010016\u20100384\u20104"},{"key":"e_1_2_13_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/jrsm.1167"},{"key":"e_1_2_13_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/rssa.12579"},{"key":"e_1_2_13_11_1","volume-title":"RStudio: Integrated Development Environment for R","author":"Posit Team","year":"2022"},{"key":"e_1_2_13_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2010.03.016"},{"key":"e_1_2_13_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/jrsm.1428"},{"key":"e_1_2_13_14_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898"},{"key":"e_1_2_13_15_1","first-page":"13","volume-title":"A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Placebo and an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis (BE VIVID)","author":"ClinicalTrials.gov","year":"2024"},{"key":"e_1_2_13_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljaf327"},{"key":"e_1_2_13_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12996"},{"key":"e_1_2_13_18_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2025.1136"},{"key":"e_1_2_13_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325\u2010024\u201002976\u2010w"},{"key":"e_1_2_13_20_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2025.1849"},{"key":"e_1_2_13_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555\u2010023\u201001012\u2010z"},{"key":"e_1_2_13_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346\u20108138.16865"},{"key":"e_1_2_13_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2024.12.018"},{"key":"e_1_2_13_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.01.072"},{"key":"e_1_2_13_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2015.09.001"},{"key":"e_1_2_13_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2023.11.060"},{"key":"e_1_2_13_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.07.040"},{"key":"e_1_2_13_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2024.03.025"},{"key":"e_1_2_13_29_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2020.1749546"},{"key":"e_1_2_13_30_1","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljad182"},{"key":"e_1_2_13_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.05.033"},{"key":"e_1_2_13_32_1","volume-title":"A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Placebo and an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis (BE VIVID)","author":"ClinicalTrials.gov","year":"2024"},{"key":"e_1_2_13_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2024.10.076"},{"key":"e_1_2_13_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.15605"},{"key":"e_1_2_13_35_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555\u2010021\u201000521\u2010z"},{"key":"e_1_2_13_36_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13671\u2010018\u20100237\u20106"},{"key":"e_1_2_13_37_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13010224"},{"key":"e_1_2_13_38_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555\u20103711"},{"key":"e_1_2_13_39_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.20387"}],"container-title":["Journal of Cosmetic Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jocd.70662","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jocd.70662","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jocd.70662","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T04:16:14Z","timestamp":1769228174000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jocd.70662"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1111\/jocd.70662"],"URL":"https:\/\/doi.org\/10.1111\/jocd.70662","archive":["Portico"],"relation":{},"ISSN":["1473-2130","1473-2165"],"issn-type":[{"value":"1473-2130","type":"print"},{"value":"1473-2165","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"2025-11-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-30","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-08","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70662"}}